Giordano Nicoletti

Istituto Ortopedico Rizzoli — Italy

Immunology and Microbiology · Life Sciences

45h-index6.0kcitations231works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(63), Sarcoma Diagnosis and Treatment(54), Monoclonal and Polyclonal Antibodies Research(35), Virus-based gene therapy research(27), Immune Cell Function and Interaction(24)

Publications231 total

Table S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Table S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Figure S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Figure S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Table S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Figure S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Supplementary Materials and Methods from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Data from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Figure S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Table S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Data from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Supplementary Materials and Methods from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
2023Open Access
Supplementary Figure 2 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Supplementary Figure 2 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Supplementary Figure 4 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Supplementary Figure 4 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Supplementary Figure 3 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Data from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Supplementary Methods from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
Supplementary Figure 5 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Pier‐Luigi Lollini(46), Patrizia Nanni(43), Lorena Landuzzi(35), Carla De Giovanni(30), Katia Scotlandi(22), Maria Cristina Manara(16), Piero Picci(16), Annalisa Astolfi(14), Stefania Croci(12), Piero Musiani(10), Stefania Benini(8), Arianna Palladini(8), Emma Di Carlo(7), Guido Forni(7), Massimo Serra(7), Manuela Iezzi(7), Federica Cavallo(6), Mario P. Colombo(6), Ilaria Rossi(5), Cinzia Ricci(5)